Table 3.
Five-Year Rates of Advanced AMD,* by Drusen Area and Predominance of Soft Indistinct Drusen At Baseline
|
Predominance of Soft Indistinct Drusen, No. (%) |
|||||||
|---|---|---|---|---|---|---|---|
| Drusen Area | Absent | Present, Not Predominant | Predominant in 1 of 3 Zones | Predominant in 2 of 3 Zones | Predominant in 3 of 3 Zones | Total | PValue, Trend Test |
| None, questionable, <C-0 | |||||||
| At risk | 879 | 879 | |||||
| NeoAMD | 1 | 1 | |||||
| CGA | 1 | 1 | |||||
| Total† | 2 (0.2) | 2 (0.2) | |||||
| ≥C-0. <C-1 | |||||||
| At risk | 602 | 6 | 35 | 0 | 0 | 643 | |
| NeoAMD | 3 | 0 | 3 | 6 | |||
| CGA | 0 | 0 | 0 | 0 | |||
| Total† | 4 (0.7) | 0 | 3 (8.6) | 7 (1.1) | .004 | ||
| ≥C-1, <C-2 | |||||||
| At risk | 294 | 20 | 121 | 27 | 1 | 463 | |
| NeoAMD | 6 | 0 | 0 | 1 | 0 | 7 | |
| CGA | 1 | 1 | 0 | 0 | 0 | 2 | |
| Total† | 7 (2.4) | 1 (5.0) | 1 (0.8) | 2 (7.4) | 0 | 11 (2.4) | .83 |
| ≥C-2, <I-2 | |||||||
| At risk | 102 | 32 | 113 | 55 | 13 | 315 | |
| NeoAMD | 4 | 1 | 3 | 2 | 1 | 11 | |
| CGA | 1 | 0 | 0 | 0 | 1 | 2 | |
| Total† | 5 (4.9) | 1 (3.1) | 3 (2.7) | 2 (3.6) | 2 (15.4) | 13 (4.1) | .75 |
| ≥I-2, <O-2 | |||||||
| At risk | 43 | 30 | 73 | 76 | 37 | 259 | |
| NeoAMD | 0 | 1 | 3 | 3 | 5 | 12 | |
| CGA | 1 | 1 | 0 | 1 | 1 | 4 | |
| Total† | 1 (2.3) | 2 (6.7) | 5 (6.8) | 5 (6.6) | 6 (16.2) | 19 (7.3) | .04 |
| ≥O-2, <0.5 DA | |||||||
| At risk | 26 | 15 | 33 | 66 | 46 | 186 | |
| NeoAMD | 0 | 1 | 2 | 5 | 8 | 16 | |
| CGA | 0 | 0 | 3 | 4 | 1 | 8 | |
| Total† | 0 | 1 (6.7) | 5 (15.2) | 10 (15.2) | 10 (21.7) | 26 (14.0) | .005 |
| ≥0.5 DA, <1.0 DA | |||||||
| At risk | 23 | 11 | 11 | 52 | 67 | 164 | |
| NeoAMD | 1 | 1 | 1 | 7 | 10 | 20 | |
| CGA | 3 | 1 | 5 | 6 | 6 | 21 | |
| Total† | 4 (17.4) | 2 (18.2) | 6 (54.5) | 14 (26.9) | 16 (23.9) | 42 (25.6) | .7 |
| ≥1.0 DA | |||||||
| At risk | 34 | 22 | 44 | 59 | 144 | 303 | |
| NeoAMD | 2 | 1 | 8 | 6 | 22 | 39 | |
| CGA | 3 | 1 | 7 | 8 | 17 | 36 | |
| Total† | 5 (14.7) | 2 (9.1) | 15 (34.1) | 15 (25.4) | 43 (29.9) | 80 (26.4) | .04 |
| Total | |||||||
| At risk | 2003 | 136 | 430 | 335 | 308 | 3212 | |
| NeoAMD | 17 | 5 | 20 | 24 | 46 | 112 | |
| CGA | 10 | 4 | 15 | 19 | 26 | 74 | |
| Total† | 28 (1.4) | 9 (6.6) | 38 (8.8) | 48 (14.3) | 77 (25.0) | 200 (6.2) | |
| P value, trend test | <.001 | .17 | <.001 | <.001 | .03 | NA | NA |
Abbreviations: AMD, age-related macular degeneration; CGA, geographic atrophy involving center of macula; DA, disc area; NA, not applicable; NeoAMD, neovascular AMD.
*
In the right eyes of 3212 participants free of advanced AMD in both eyes at baseline. Cells that cannot, by definition, have entries are blank.
†
Numbers given for NeoAMD and CGA represent eyes with this outcome only; where the total exceeds the sum of NeoAMD +CGA, the difference represents eyes that were graded as both NeoAMD and CGA, usually at different visits.